Forte Biosciences, Inc.
FBRX
$11.16
-$0.10-0.89%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -58.18% | -0.55% | -24.63% | -28.28% | 273.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.67% | 106.61% | 15.20% | -15.53% | 41.89% |
| Operating Income | 9.67% | -106.61% | -15.20% | 15.53% | -41.89% |
| Income Before Tax | 10.09% | -111.00% | -21.85% | 15.70% | -40.64% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 10.09% | -111.00% | -21.85% | 15.70% | -40.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.09% | -111.00% | -21.85% | 15.70% | -40.64% |
| EBIT | 9.67% | -106.61% | -15.20% | 15.53% | -41.89% |
| EBITDA | 9.71% | -106.68% | -15.15% | 15.62% | -- |
| EPS Basic | 85.87% | 65.88% | 63.26% | 30.90% | 35.84% |
| Normalized Basic EPS | 85.87% | 65.88% | 63.27% | 30.90% | 35.84% |
| EPS Diluted | 85.87% | 65.88% | 63.26% | 30.90% | 35.84% |
| Normalized Diluted EPS | 85.87% | 65.88% | 63.27% | 30.90% | 35.84% |
| Average Basic Shares Outstanding | 536.47% | 518.40% | 231.69% | 21.99% | 119.17% |
| Average Diluted Shares Outstanding | 536.47% | 518.40% | 231.69% | 21.99% | 119.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |